Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape

Autor: Margrith E. Mattmann, Sydney L. Stoops, Craig W. Lindsley
Rok vydání: 2011
Předmět:
Zdroj: Expert Opinion on Therapeutic Patents. 21:1309-1338
ISSN: 1744-7674
1354-3776
DOI: 10.1517/13543776.2011.587959
Popis: Akt plays a pivotal role in cell survival and proliferation through a number of downstream effectors; unregulated activation of the PI3K/PTEN/Akt pathway is a prominent feature of many human cancers. Akt is considered an attractive target for cancer therapy by the inhibition of Akt alone or in combination with standard cancer chemotherapeutics. Both preclinical animal studies and clinical trials in humans have validated Akt as an important target of cancer drug discovery.A historical perspective of Akt inhibitors, including PI analogs, ATP-competitive and allosteric Akt inhibitors, along with other inhibitory mechanisms are reviewed in this paper with a focus on issued patents, patent applications and a summary of clinical trial updates since the last review in 2007.A vast diversity of inhibitors of Akt, both small molecule and biologic, have been developed in the past 5 years, with over a dozen in various phases of clinical development, and several displaying efficacy in humans. While it is not yet clear which mechanism of Akt inhibition will be optimal in humans, or which Akt isoforms to inhibit, or whether a small molecule or biologic agent will be best, data to all of these points will be available in the near future.
Databáze: OpenAIRE